Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493870 · ClinicalTrials.gov registry record · Phase 3
TAC Versus TC for Adjuvant Breast Cancer
A Phase 3 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,961
- Enrollment target
NCT00493870: Completed Phase 3 study, sponsored by US Oncology Research.
NCT00493870 is a Phase 3 study that has completed, run by US Oncology Research. The registered enrollment target is 1,961 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (154% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493870, a Phase 3 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,961 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Primary Outcome
The primary objective of the study is to compare the 3-year invasive disease-free survival (IDFS) of adjuvant TC versus TAC as treatment for early stage HER2-negative breast cancer among analyzed ITT patients. ITT patients are all patients who were randomized, whether or not they followed protocol. IDFS, defined as the time from the date of randomization to local recurrence following mastectomy, invasive local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distan
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,961 participants |
| Start Date | 2007-05-29 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 3 |
What the finished NCT00493870 record still lists
NCT00493870 is an interventional study that assigns participants to a tested intervention. Its 1,961 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (154% higher).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00493870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00493870 about?
NCT00493870 is a clinical study titled "TAC Versus TC for Adjuvant Breast Cancer". The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
What is the current status of trial NCT00493870?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,961 participants. The study started on 2007-05-29. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT00493870?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00493870?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00493870's enrollment target sits among peer trials
1,961 107th of 2000 higher than 1,894 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI